| That actually proves my point, really | At the same time, Canopy Growth decided to fill in every single office position they could as quickly as possible showing that they were an advanced and sophisticated operation |
|---|---|
| How much will be worth in 2021, 2022, 2023? Now what But here's the thing: Those gains may not be shared equally, and on Jefferies' list of the marijuana stocks it likes most, it's mostly lesser-known names such as Cresco, Curaleaf, and Green Thumb that predominate | They are valued too high relative to book, they do not have decent prospects of profitability in the near future, are likely to see market share dissipate, and generally, are losing too much money quarter after quarter |
First, it is… ahem, or was, the biggest on the to get involved in but, never one of the to buy.
| Revenues Revenues are largely not happening | Because of this, cannabis investing was having its heyday and cannabis companies saw their stocks soar |
|---|---|
| Back in 2020, five states voted to legalize cannabis, including traditionally conservative states like Montana and Arizona | But, fast forward to 2020, and Canada finally got it right |
| For one, the Canadian government was too restrictive on taxes | This is a once-in-a-lifetime opportunity to get involved in cannabis investing and capitalize on a new industry that is booming… But, only some of the stocks are going to be real winners |
|---|---|
| Canopy growth immediately began spending money on infrastructure for growing large quantities of cannabis in a short period of time | But for long-term investors, Jefferies' note holds good news, too |